Eli Lilly delivered good news for many people with diabetes by announcing 70% price reductions for your prescription insulins and an expansion of its Insulin Value program that limits patient out-of-pocket costs to $35 or less per month.
The laboratory is adopting these measures to facilitate access to insulin and help Americans who may have difficulties to get by in a complex healthcare system where affordable insulin is hard to come by.
Discounts that will be applied:
Lilly will lower the list price of its non-brand insulin Insulin Lispro Injection 100 units/mL, $25as of May 1, 2023.
The Humalog (insulin lispro injection) 100 units/ml for type 1 and 2 diabetes, which is the most commonly prescribed, will be discounted by 70%which will take effect in the fourth quarter of 2023.
The laboratory also announced the launch of the injection of Rezvoglar TM (insulin glargine-aglr), a basal insulin that is biosimilar and interchangeable with Lantus injection (insulin glargine), retailing for $92 per pack of five KwikPens, starting in April 2023.
“While the current health care system provides access to insulin for the majority of people with diabetes, still does not provide affordable insulin for all and that must changesaid David A. Ricks, Chairman and CEO of Eli Lilly.
“The aggressive price cuts we are announcing today should make a real difference for Americans with diabetes.. Because these price cuts will take time for the insurance system and pharmacies to implement, we are taking an extra step to immediately limit out-of-pocket costs for patients who use insulin and are not covered by the recent cap on insulin. Medicare Part D.”
Lilly is also making it easier for more people with diabetes to get their insulins. Effective immediately, the laboratory will limit out-of-pocket costs on $35 at participating retail pharmacies for people with commercial insurance who use the drug.
People who do not have insurance can still go to InsulinAffordability.com and immediately download the Insulin Value Program Savings Card to receive insulin for $35 per months.
“We’re pushing for a price review change for older insulins, but we know that 7 out of 10 Americans don’t use insulin. We call on legislators, employers and others to join us in making insulin more affordableRicks said. “For the past century, Lilly has focused on inventing new and improved insulins and other medicines that address the impact of diabetes and improve patient outcomes. Our work to discover new and better treatments is far from over. We will not stop until all people with diabetes control their disease and can get the insulin they need.”
In the coming weeks, Lilly will launch a national public awareness campaign to help ensure that all insulin users understand how to access the company’s affordability solutions. For more information, you can visit Lilly.com/insulin.
